Albireo Pharma/ US01345P1066 /
2023-03-02 10:00:00 PM | Chg. - | Volume | Bid1:36:55 AM | Ask1:56:51 AM | High | Low |
---|---|---|---|---|---|---|
44.1500USD | - | 1.24 mill. Turnover: 52.59 mill. |
44.1000Bid Size: 1,000 | 44.3000Ask Size: 300 | 44.9000 | 43.9900 |
GlobeNewswire
03-18
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
GlobeNewswire
2023-11-01
MBX Biosciences Announces Appointment of Michelle Graham as Chief Human Resources Officer
GlobeNewswire
2023-10-23
Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome
GlobeNewswire
2022-03-29
Albireo Completes Enrollment in Pivotal Phase 3 ASSERT Study of BylvayTM (odevixibat) in Alagille Sy...
GlobeNewswire
2022-02-14
Albireo Announces Publication of the PICTURE Study Highlighting the Caregiver Impact of PFIC, a Rare...
GlobeNewswire
2021-12-02
Albireo Expands Leadership with Constantine Chinoporos as Chief Business Officer
GlobeNewswire
2021-11-12
Albireo Announces New Phase 3 Data for Bylvay™ (odevixibat) in PFIC and First Reveal of New Next Gen...